Reach Us +1-218-451-2974


Blood Biomarkers In Preclinical Alzheimer Disease | 46201
ISSN: 2161-0460

Journal of Alzheimers Disease & Parkinsonism
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences
Google scholar citation report
Citations : 2275

Journal of Alzheimers Disease & Parkinsonism received 2275 citations as per google scholar report

Journal of Alzheimers Disease & Parkinsonism peer review process verified at publons
Indexed In
  • Index Copernicus
  • Google Scholar
  • Sherpa Romeo
  • Open J Gate
  • Genamics JournalSeek
  • Academic Keys
  • JournalTOCs
  • China National Knowledge Infrastructure (CNKI)
  • Electronic Journals Library
  • RefSeek
  • Hamdard University
  • OCLC- WorldCat
  • SWB online catalog
  • Virtual Library of Biology (vifabio)
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
Share This Page

Blood biomarkers in preclinical Alzheimer Disease

4th International Conference on Vascular Dementia

Howard J Federoff

University of California, USA

Keynote: J Alzheimers Dis Parkinsonism

DOI: 10.4172/2161-0460.C1.017

Our group has studied a longitudinal cohort of seniors, >75 yrs, to discover and validate peripheral blood measures that can accurately predict which cognitively normal subjects will progress to amnestic Mild Cognitive Impairment (aMCI) or Alzheimer disease (AD) in a three year period. We initially reported on plasma metabolites which are now more accurate as a diagnostic. We have extended this work on plasma metabolomics and have discovered and validated a panel of 24 analytes that predict phenoconversion to Alzheimer’s disease with accuracy of >96%.

Howard J Federoff over sees the clinical, medical educational, and research missions, as a Vice Chancellor for Health Affairs and CEO of UC Irvine Health. He investigates gene therapy and neurodegenerative diseases. He has published greater than 250 articles and serves on the editorial boards of five journals. He Chaired the NIH Recombinant DNA Advisory Committee and currently Chairs the Gene Therapy Resource Program for NHLBI. He is President of the American Society for Experimental Neurotherapeutics. He received MS, PhD, and MD degrees from the Albert Einstein College of Medicine, did his internship, residency, and clinical and research fellowships at Massachusetts General Hospital/Harvard Medical School. He is a Fellow of the AAAS and National Academy of Inventors.

Email: [email protected]